黑素细胞:银屑病中HLA-C*06:02限制性自身免疫反应的靶细胞
该综述基于对银屑病致病性CD8+ T细胞中Vα3S1/Vβ13S1 T细胞受体的无偏分析,总结HLA-C*06:02通过自身抗原呈递驱动针对黑素细胞的自身免疫反应,并鉴定ADAMTSL5为黑素细胞自身抗原。作者认为银屑病基于黑素细胞特异性免疫反应,HLA-C*06:02可能通过该自身免疫通路易感银屑病,将银屑病解释为原发性自身免疫性皮肤病。
要点
- HLA-C*06:02是银屑病主要风险等位基因,通过呈递黑素细胞自身抗原驱动CD8+ T细胞反应。
- ADAMTSL5被鉴定为黑素细胞自身抗原,是HLA-C*06:02限制性自身免疫反应的靶点。
- 银屑病可被视为由黑素细胞特异性免疫反应驱动的原发性自身免疫性皮肤病。
核心结论
- 银屑病基于针对黑素细胞的特异性自身免疫反应,HLA-C*06:02可能通过该新鉴定的自身免疫通路易感银屑病。
- 将黑素细胞鉴定为银屑病免疫反应的靶细胞,可将银屑病解释为原发性自身免疫性皮肤病。
研究设计与样本
- 综述,基于对银屑病致病性CD8+ T细胞中Vα3S1/Vβ13S1 T细胞受体的无偏分析,结合HLA功能与T细胞受体-抗原识别相关免疫机制进行总结。
主要发现
- HLA-C*06:02通过自身抗原呈递指导针对黑素细胞的自身免疫反应。
- ADAMTSL5被鉴定为黑素细胞自身抗原。
- HLA I类分子呈递来自胞质内蛋白的肽抗原,因此HLA I类限制性自身反应性CD8+ T细胞反应必须针对特定靶细胞类型。
临床怎么用
- 将银屑病视为黑素细胞特异性自身免疫反应,为理解HLA-C*06:02的致病作用提供新视角。
局限性
- 需更详细解释该通路,综述基于既有发现进行整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-C*06:02 is the main psoriasis risk allele. By the unbiased analysis of a Vα3S1/Vβ13S1 T-cell receptor from pathogenic psoriatic CD8+ T cells, we had recently proven that HLA-C*06:02 directs an autoimmune response against melanocytes through autoantigen presentation in psoriasis and identified ADAMTSL5 as a melanocyte autoantigen. We concluded that psoriasis is based on a melanocyte-specific immune response and that HLA-C*06:02 may predispose to psoriasis via this newly identified autoimmune pathway. Understanding this pathway, however, requires more detailed explanation. It is based on the fact that an HLA class I-restricted autoreactive CD8+ T-cell response must be directed against a particular target cell type, because HLA class I molecules present peptide antigens generated from cytoplasmic (i.e., intracellular) proteins. This review summarizes the findings on the melanocyte-specific autoimmune response in the context of the immune mechanisms related to HLA function and T-cell receptor-antigen recognition. Identifying melanocytes as target cells of the psoriatic immune response now explains psoriasis as a primary autoimmune skin disease.
引用
- Prinz JC. Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis. J Invest Dermatol. 2017. PMID: 28941475. doi:10.1016/j.jid.2017.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。